GO
Loading...

Enter multiple symbols separated by commas

Actavis Inc

More

  • *Deal builds on last year's purchase of Almirall drugs. LONDON, Feb 5- AstraZeneca has agreed to buy Actavis' branded respiratory drug business in the United States and Canada for an initial $600 million as it seeks external deals to ensure growth. AstraZeneca will also pay another $100 million, after Actavis agreed to a number of changes to ongoing agreements...

  • LONDON, Feb 5- AstraZeneca said on Thursday it had agreed to buy Actavis' branded respiratory drug business in the United States and Canada for an initial payment of $600 million as it seeks external deals to ensure growth. The British group, which saw off a $118 billion bid by Pfizer last year, said its sales in the fourth quarter fell 2 percent to $6.68 billion,...

  • Last month's return on Treasuries was the biggest since a 3.54 percent jump in December 2008, according to an index compiled by Bank of America Merrill Lynch. "We are giving back some of the gains from the short-covering rally last week," said Suvrat Prakash, interest rate strategist at HSBC Securities USA in New York. Apple Inc. planned to raise $5 billion in the...

  • Jan 29- Bankrupt drugmaker Dendreon Corp has reached a stalking-horse deal with Canada's Valeant Pharmaceuticals International Inc to sell the worldwide rights to its cancer vaccine, Provenge, and certain assets for $296 million. The deal is subject to higher and better bids and extended the bid deadline to Feb. 10 for interested parties to participate in an...

  • WASHINGTON, Jan 26- The U.S. Supreme Court on Monday sent three patent cases, including one dispute over Shire Plc's Lialda drug, back to a lower court for further proceedings in light of a ruling the justices issued last week. Watson Pharmaceuticals, U.S. Supreme Court, No. 14-206.. Butamax Advanced Fuels LLC and Lighting Ballast Control LLC v.

  • BOSTON, Jan 16- Eric Mindich's $8.5 billion hedge fund, Eton Park Capital Management, is now ready to pick through the debt of beaten-up energy companies, an area it avoided last year as the price of oil tumbled. Eton Park dropped mortgage companies Fannie Mae and Freddie Mac with a big profit before a U.S. judge threw out a lawsuit filed by shareholders to prevent the...

  • SAN FRANCISCO, Jan 15- Allergan Inc Chief Executive David Pyott is close to joining the board of directors of Actavis Plc, which reached a deal to buy the Botox-maker for $66 billion in November, three people familiar with the matter said on Thursday. One investor who attended the meeting told Reuters that adding Pyott to the board could lend more credibility to...

  • *Asset could be worth up to 2 bln euros- Bloomberg. FRANKFURT, Jan 15- German drugmaker Boehringer Ingelheim said it is considering the sale of its U.S.-based generics unit Roxane Labs to put a stronger focus on the development and sale of new pharmaceuticals. A company spokeswoman said Boehringer was not a specialist in generics and was therefore considering...

  • Hedge funds playing buy-and-hold, and losing Monday, 24 Nov 2014 | 10:54 AM ET
    An Apple store in New York.

    Hedge funds aren't changing their stock holdings much despite poor performance compared with the broader stock market.

  • Ackman has the luck of a loser, to the tune of $2.2B Tuesday, 18 Nov 2014 | 7:02 AM ET
    Bill Ackman

    Heads he wins. Tails he wins. That was the situation Bill Ackman found himself in — or perhaps more accurately, orchestrated — on Monday.

  • Mega-mergers are popular again on Wall Street Tuesday, 18 Nov 2014 | 6:47 AM ET

    Deals worth $100 billion on Monday put the Street on pace for a year rivaling the dot-com bubble era and the private equity surge just before the financial crisis.

  • Early movers: AAPL, AZN, SHPG, FB, MSFT, DB & more Tuesday, 23 Sep 2014 | 7:41 AM ET
    A trader works on the floor of the New York Stock Exchange in New York.

    Some of the names on the move ahead of the open.

  • Early movers: HSY, SHLD, BX, BA, LMNT, BABA & more Tuesday, 16 Sep 2014 | 7:35 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Cramer: Get this company on your radar, now! Monday, 4 Aug 2014 | 6:33 PM ET

    Ahead of earnings, Jim Cramer thinks you should know about this stock and the potential it presents.

  • Cooperman: Buy these stocks now Wednesday, 16 Jul 2014 | 12:22 PM ET
    Omega Advisors CEO Leon G. Cooperman speaks at the CNBC Institutional Investor Delivering Alpha Conference in New York.

    Billionaire investor Leon Cooperman gave 12 stock recommendations at the Delivering Alpha conference Wednesday.

  • Allergan to shareholders: Ignore Pershing Square Friday, 11 Jul 2014 | 6:31 PM ET
    A vial of Allergan’s Botox is arranged next to boxes for a photograph at a doctor's office in Manhattan Beach, Calif.

    Allergan told its stockholders not to respond to Pershing Square Capital Management's proposal to replace a majority of the board.

  • Early movers: NFLX, WYNN, APP & more Tuesday, 1 Jul 2014 | 7:56 AM ET

    Some of the names on the move ahead of the open.

  • Why rivals are jealous of Pfizer's AstraZeneca deal Thursday, 1 May 2014 | 7:15 AM ET
    U.S. drugmaker Pfizer proposed buying AstraZeneca for about 58.8 billion pounds ($98.7 billion) in what would rank as the industry's biggest-ever takeover, surpassing Pfizer's $64 billion purchase of Wyeth in 2009.

    As rivals assessed what Pfizer's play for AstraZeneca could mean for the industry, one aspect touched nearly everyone: What it could mean for a U.S. tax loophole.

  • Focus is on Fed, but this may move markets instead Wednesday, 30 Apr 2014 | 9:30 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Wall Street has its eye on the Federal Reserve's meeting, but a slew of data is likely to have more influence on stocks Wednesday.

  • Early movers: CMCSA, PFE, AZN, GE & more Monday, 28 Apr 2014 | 8:02 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.